DrugPatentWatch Database Preview
Patent: 10,053,498
» See Plans and Pricing
Summary for Patent: 10,053,498
| Title: | Compositions comprising serum albumin and p53 peptides fusion proteins |
| Abstract: | The present invention relates to compositions useful in inhibiting Bcl-XL or MCL-1 and disrupting p53-MDM2 and p53-MDMX interactions, and methods of using those compositions for treating a subject for conditions responsive to increasing p53 mediated activity or promoting p53 independent apoptosis, such as treating cancer. In some aspects, the compositions of this invention relate to fusion polypeptides comprising a human serum polypeptide and a p53-peptide, which can be, in some aspects, a p53 derived peptide and/or a p53 activating peptide. |
| Inventor(s): | Li; Zhiyu (Woodstock, MD), Parker; Michelle (Leander, TX) |
| Assignee: | University of the Sciences of Philadelphia (Philadelphia, PA) |
| Application Number: | 14/948,010 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,053,498
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | Orphan | search |
| Wyeth Pharms Inc | MYLOTARG | gemtuzumab ozogamicin | VIAL;SINGLE-DOSE | 761060 | 001 | 2018-04-09 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | Orphan | search |
| Novartis | KESIMPTA | ofatumumab | SOLUTION;SUBCUTANEOUS | 125326 | 002 | 2009-10-26 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,053,498
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016081897 | Start Trial |
| United States of America | 2016145314 | Start Trial |
| United States of America | 2019062388 | Start Trial |
| European Patent Office | 3220953 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
